Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Isarna Therapeutics GmbH
ClinicalTrials.gov Identifier:
NCT00844064
First received: February 12, 2009
Last updated: November 18, 2011
Last verified: November 2011
  Purpose

In this national Phase I dose-escalation study the safety and tolerability of AP 12009 is evaluated in adult patients with advanced tumors known to overproduce TGF-β2, who are not or no longer amenable to established therapies.


Condition Intervention Phase
Pancreatic Neoplasms
Melanoma
Colorectal Neoplasms
Drug: AP 12009
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter Dose-Escalation Study to Evaluate the Safety and Tolerability of AP 12009 (Trabedersen), Administered Intravenously in Patients With Advanced Tumors Known to Overproduce TGF-β2.

Resource links provided by NLM:


Further study details as provided by Isarna Therapeutics GmbH:

Primary Outcome Measures:
  • To determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT) of two cycles of AP 12009 administered intravenously at weekly intervals and for four days every other week. [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To determine the safety and tolerability of AP 12009 administered intravenously at weekly intervals and for four days every other week. [ Designated as safety issue: Yes ]
  • To assess the plasma pharmacokinetic profile of AP 12009 administered intravenously at weekly intervals and for four days every other week. [ Designated as safety issue: Yes ]
  • To establish a suitable determination method and to assess the urine pharmacokinetic profile of AP 12009 administered intravenously for four days every other week. [ Designated as safety issue: Yes ]
  • To determine the effect of AP 12009 administered intravenously at weekly intervals and for four days every other week on TGF-β2 plasma concentration levels. [ Designated as safety issue: No ]
  • To determine the potential antitumor activity of AP 12009 administered intravenously at weekly intervals and for four days every other week, as assessed by the effect on tumor size and tumor markers. [ Designated as safety issue: No ]

Enrollment: 62
Study Start Date: January 2005
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AP 12009 Drug: AP 12009

Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.

Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles


Detailed Description:

The purpose of this dose-finding study is to evaluate the safety and tolerability of AP 12009. Two fixed dose-escalation schemes with predefined steps and increasing increments have been selected to determine the maximum tolerated dose (MTD) as well as the dose-limiting toxicity (DLT). At least two cycles of AP 12009 are administered intravenously in adult patients with no further acknowledged treatment options.

AP 12009 (trabedersen) is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human Transforming Growth Factor beta 2 (TGF-beta-2). The growth factor TGF-beta plays a key role in malignant progression of various tumors by inducing proliferation, invasion, metastasis, angiogenesis, and escape from immunosurveillance. In patients with pancreatic cancer, colorectal cancer, and metastatic melanoma the TGF-beta-2 overexpression is associated with disease stage, clinical prognosis, and the immunodeficient state of the patients.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent.
  2. Age: 18-75 years.
  3. Male or non-pregnant, non-lactating female.
  4. a.Pancreatic cancer: Histologically or cytologically confirmed diagnosis, stage IVA or IVB (AJCC, 1997).

    b. Melanoma: Histologically or cytologically confirmed diagnosis, stage III or IV (AJCC, UICC).

    c. Colorectal cancer: Histologically or cytologically confirmed diagnosis, stage III or IV (AJCC, UICC), excluded from the last cohort.

  5. Patient is not or no longer amenable to established forms of therapy.
  6. At least one measurable lesion.
  7. Karnofsky performance status of at least 80%.
  8. Recovery from acute toxicity caused by any previous therapy.
  9. Adequate organ function as assessed by the following laboratory values:

    • Serum creatinine and urea < 2 times the upper limit of normal (ULN).
    • ALT and AST < 3 ULN (in case of a liver metastasis: < 5x ULN); alkaline phosphatase < 3 ULN; and bilirubin < 2.5 mg/dL.
    • Prothrombin time < 1.5 INR and PTT < 1.5 times the upper limit of normal.
    • Hemoglobin > 9 g/dL.
    • Platelets > 100 x 10E9/L.
    • WBC > 3.0 x 10E9/L.
    • Absolute Neutrophil Count (ANC) > 1.5 x 10E9/L.

Exclusion Criteria:

  1. Patient unable to comply with the protocol regulations.
  2. Pregnant or lactating female.
  3. Antitumor radiation therapy within 12 weeks, tumor surgery within 4 weeks or any other therapy with established antitumor effects within 2 weeks prior to study entry.
  4. The patient takes or is likely to need other prohibited concomitant medication. Administration of corticosteroids should be strictly avoided during the course of the study.
  5. Patient's participation in another clinical trial with investigational medication within 30 days prior to study entry.
  6. History of brain metastases. In the case of suspected brain metastases a CT scan of the skull will be performed (not mandatory in asymptomatic patients).
  7. Clinically significant cardiovascular abnormalities such as refractory hypertension, congestive heart failure, unstable angina, or poorly controlled arrhythmia, or a myocardial infarction within 6 months prior to treatment.
  8. Gastric or duodenal ulcers within 6 months before study entry or is at risk of gastrointestinal ulceration due to high consumption of NSAIDs.
  9. An active infection with HIV, HBV, or HCV.
  10. Clinically significant acute viral, bacterial, or fungal infection.
  11. Acute medical problems that may be considered to become an unacceptable risk, or any conditions that might be contraindications for starting study treatment.
  12. History of allergies to reagents used in this study.
  13. Drug abuse or extensive use of alcohol.
  14. Significant psychiatric disorders/ legal incapacity or limited legal capacity.
  15. History of Long QT Syndrome or QTc time ≥ 480 msec in screening/baseline ECGs. The average QTc time is to be calculated from three separate ECGs performed prior to start of infusion: two ECGs performed at Screening/Baseline (with a minimum 1-hour interval in between) and one performed within 1 hour prior to start of infusion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00844064

Locations
Germany
Universitätsmedizin Berlin Charité
Berlin, Germany, 10117
Universitätsklinik und Poliklinik für Innere Medizin I
Halle (Saale), Germany, 06120
Hautklinik der Ruprecht-Karls-Universität Heidelberg
Heidelberg, Germany, 69115
Universitätsklinikum Schleswig-Holstein
Kiel, Germany, 24105
Krankenhaus rechts der Isar, II. Medizinische Klinik und Poliklinik
München, Germany, 81675
Universität Münster, Klinik und Poliklinik für Hautkrankheiten
Münster, Germany, 48149
Klinik und Poliklinik für Dermatologie
Regensburg, Germany, 93053
Klinik und Poliklinik für Innere Medizin I
Regensburg, Germany, 93042
Universitäts-Hautklinik, Sektion Dermatologische Onkologie
Tübingen, Germany, 72076
Universitätsklinikum Ulm, Zentrum für Innere Medizin
Ulm, Germany, 89081
Sponsors and Collaborators
Isarna Therapeutics GmbH
Investigators
Study Chair: Helmut Oettle, MD Charité Berlin Campus Virchow-Klinikum
  More Information

Additional Information:
No publications provided

Responsible Party: Isarna Therapeutics GmbH
ClinicalTrials.gov Identifier: NCT00844064     History of Changes
Other Study ID Numbers: AP 12009-P001
Study First Received: February 12, 2009
Last Updated: November 18, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Isarna Therapeutics GmbH:
Pancreatic cancer
Metastatic melanoma
Advanced tumor
Targeted therapy
Antisense
Transforming Growth Factor beta 2
Dose escalation

Additional relevant MeSH terms:
Neoplasms
Melanoma
Colorectal Neoplasms
Pancreatic Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Trabedersen
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 30, 2014